Regen BioPharma Inc financial data

Symbol
RGBP, RGBPP on OTC
Location
4700 Spring St #304, La Mesa, CA
State of incorporation
NV
Fiscal year end
September 30
Latest financial report
Nov 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.73 % +1.87%
Debt-to-equity -103 % +3.91%
Return On Equity 17.5 %
Return On Assets -535 % -269%
Operating Margin -309 % +34.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.51M shares +33.3%
Common Stock, Shares, Outstanding 5.26M shares +50%
Entity Public Float 6.59M USD
Common Stock, Value, Issued 527 USD +49.7%
Weighted Average Number of Shares Outstanding, Basic 4.11M shares +16.2%
Weighted Average Number of Shares Outstanding, Diluted 4.21M shares +24.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 127K USD -17.8%
Revenue from Contract with Customer, Excluding Assessed Tax 31.6K USD 0%
Research and Development Expense 154K USD -27.6%
General and Administrative Expense 58.9K USD +31%
Costs and Expenses 655K USD -29.1%
Operating Income (Loss) -418K USD +39.1%
Nonoperating Income (Expense) -227K USD -111%
Net Income (Loss) Attributable to Parent -867K USD +18.5%
Earnings Per Share, Basic -0.03 USD/shares 0%
Earnings Per Share, Diluted -0.03 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 716 USD
Accounts Receivable, after Allowance for Credit Loss, Current 94.9K USD
Assets, Current 160K USD +22%
Assets 178K USD -49.8%
Accounts Payable, Current 29.7K USD -0.02%
Liabilities, Current 5.37M USD +1.2%
Liabilities 5.37M USD -1.58%
Retained Earnings (Accumulated Deficit) -20.6M USD -4.39%
Stockholders' Equity Attributable to Parent -5.19M USD -1.76%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -5.18M USD -4.99%
Liabilities and Equity 178K USD -49.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -162K USD -1452%
Net Cash Provided by (Used in) Financing Activities 166K USD
Common Stock, Shares Authorized 5.8B shares +1060%
Common Stock, Shares, Issued 5.26M shares +50%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.8K USD +8838%
Deferred Tax Assets, Valuation Allowance 4.33M USD +4.39%
Deferred Tax Assets, Gross 4.33M USD +4.39%
Deferred Tax Assets, Operating Loss Carryforwards 20.6M USD +397%
Preferred Stock, Shares Authorized 800M shares 0%
Additional Paid in Capital 14.7M USD +5.58%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 64K USD -29.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%